Enhancing GLP-1 Care With Lifestyle Support
Research Report by CARAVAN Wellness
GLP-1 medications have changed how millions of people approach weight and metabolic health. Adoption has been remarkably fast. By late 2025, roughly 1 in 8 U.S. adults reported currently taking a GLP-1 drug, about double the share from eighteen months earlier, according to KFF polling. The American Diabetes Association has also noted that the number of Americans taking these medications rose nearly sixfold over five years. More than 57 million privately insured adults now meet the clinical criteria for treatment.
The early experience is often genuinely encouraging. People report less hunger, easier portion control, and more consistency in their eating, and for many, meaningful change feels manageable for the first time. The efficacy is real: one analysis cited by the Peterson Health Technology Institute found that people taking GLP-1s lose substantially more weight than with diet and exercise alone.
But early momentum does not guarantee long-term results. What happens after the first few months depends less on the medication and more on something it cannot supply on its own: durable daily habits. The research on real-world outcomes makes this gap concrete, and it is the reason a growing number of employers and health plans are pairing GLP-1 access with structured lifestyle support.
Where the Gap Starts to Show
GLP-1 treatments act on appetite and physiology. They do not teach people how to build routines that last, and the consequences of that gap appear clearly in real-world data.
Most people stop within a year. A nationwide Danish registry study of more than 77,000 adults found that 52% discontinued semaglutide within the first year, and US pharmacy-claims data from Prime Therapeutics shows persistence falling to roughly 15% by two years and about 14% on Wegovy by three. Because GLP-1s only work while people keep taking them, this matters: a 2025 study found real-world weight loss of about 7.7% on semaglutide and 12.4% on tirzepatide after a year — roughly half of clinical-trial results — driven largely by early discontinuation. A Cleveland Clinic analysis put the gap starkly: patients who stopped within three months lost only about 3.6% of body weight, versus 11.9% or more for those who stayed on treatment.
Weight often returns when the medication stops. Across multiple observational studies, a meaningful share of patients regain weight after their last prescription, and weight regain after discontinuation is a well-documented pattern.
Weight loss is not only fat. Losing muscle along with fat is one of the most discussed risks. In the pivotal STEP 1 trial of semaglutide, roughly 45% of the weight lost was lean mass; in the SURMOUNT-1 trial of tirzepatide, the figure was about 34%, and reviews commonly cite that up to 40% of GLP-1 weight loss can come from lean mass. Body composition frequently still improves overall, and some of this change is a normal adaptation to weight loss rather than a drug effect. But lean mass matters for metabolism, blood-sugar control, and bone strength, and the loss is largest when no countermeasures are in place.
Reduced appetite can mean inadequate nutrition. The same appetite suppression that makes eating less feel effortless can lead to under-eating, missed protein targets, and poor nutritional quality if intake is not actively managed.
None of these issues originate in the medication itself. They come from what happens, or fails to happen, around it.
From Treatment to Daily Behavior
GLP-1 medications can make behavior change feel easier, but they do not replace it. People still need to adjust how they eat, move, and structure their day, and without guidance those adjustments can be unclear or inconsistent. Smaller appetites can tip into under-eating; shifting hunger cues can make meal timing harder to manage; and the initial motivation that comes with early progress can fade if no routine is there to carry it.
This is where ongoing guidance matters, and the clinical consensus is clear. A 2025 global working group concluded that getting the most from GLP-1 therapy takes more than the medication alone, it requires combining it with nutrition, physical activity, and side-effect management.
What Support Looks Like in Practice
The most effective support focuses on simple, repeatable behaviors, and the evidence points to a few priorities.
Protein, spread through the day. To help preserve muscle during weight loss, clinical guidelines recommend eating more than 1.2 grams of protein per kilogram of body weight each day, spread evenly across meals, a target set out by Almandoz and colleagues in Obesity. When appetite is suppressed, hitting that target takes intention: prioritizing protein, keeping portions nutritious, and staying hydrated.
Strength training to protect muscle. Resistance training is the most direct way to hold on to muscle while losing weight. Reviews of GLP-1 therapy and exercise find that pairing the medication with a structured diet and exercise leads to more weight loss than either alone, steers loss toward fat instead of muscle, and helps people keep their results even after stopping the drug. The goal is consistency, not intensity.
Small, stabilizing routines. Regular meals, light and consistent movement, and healthy sleep habits create stability over time. These are exactly the kinds of small, repeatable behaviors that build into durable routines.
Attention to the emotional side of eating. Food habits are often tied to stress and emotion. Helping people recognize those patterns supports more consistent choices and makes the other behaviors easier to maintain.
The common thread is that the medication handles appetite, while everything that protects long-term health, muscle, nutrition, strength, and stable routines, depends on behaviors built around it.
Why Content Plays a Role
Many organizations are moving beyond just covering the medication to supporting the daily habits that make its results last. A March 2026 Harris Poll conducted for Wondr Health found that 65% of employed adults would be more likely to use a GLP-1 if their employer covered part of the cost, while 56% said they would pay out of pocket if their employer offered a behavioral support program to help manage weight loss. At the same time, employer coverage is expanding: according to the KFF Employer Health Benefits Survey, 43% of firms with 5,000 or more employees covered GLP-1s for weight loss in their health plan in 2025.
Increasingly, the support comes as content and guidance, not clinical care alone. It helps people actually apply what they’re learning. In practice that often includes short, practical videos and walkthroughs, guided programs that build habits over time, and personalized recommendations based on a person’s behavior.
Scaling Support Across Populations
For organizations with large or global audiences, consistency is difficult to achieve. Content needs to work across different languages, cultural perspectives on food and health, and everyday lifestyles. A systematic review of culturally adapted digital health interventions found that adaptation, combining language translation with culturally resonant content and stakeholder input, was associated with dropout rates below 11%, while surface-level adaptation such as translation alone showed dropout as high as 56%.
Support also needs to fit into the platforms people already use, so they can reach it without extra steps. When guidance is part of the experience from the start rather than added later, people are more likely to engage with it.
Why This Matters
GLP-1 medications create a strong starting point. They can deliver weight loss and metabolic improvements that lifestyle changes alone often struggle to achieve in the short term. But the real-world data is consistent: long-term outcomes depend on whether people can build habits that hold beyond the initial phase, and most people, left without support, do not stay on treatment long enough or build the routines needed to maintain their progress.
Closing that gap is where content and guidance earn their place. Clinical care sets the treatment in motion, but the day-to-day work of eating enough protein, training to protect muscle, and holding steady routines happens between appointments. This is precisely where well-designed content reaches people. Short, practical, and scalable guidance delivered in the flow of everyday life is what translates a prescription into sustained behavior.
For employers and health plans, this reframes the goal. The decision is no longer only whether to provide access to the medication, but whether to support the daily behaviors that turn short-term progress into lasting change. The medication opens a window. Protein, strength, nutrition, and stable routines are what determine whether the gains last once that window begins to close.
